Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Chapman LE[original query] |
---|
Utilization of surgical resources during the USNS COMFORT humanitarian mission to the Americas, June to October 2007
Hartgerink BJ , Chapman LE , Stevenson J , Donahue TF , Pagliara C . Mil Med 2010 175 (9) 638-646 In 2007, the United States Navy Ship (USNS) COMFORT (T-AH 20), a full-capability medical treatment facility, departed for Partnership for the Americas, her first large-scale humanitarian civic assistance (HCA) mission. Analysis of operational data describes surgical resource utilization. Lessons from previous military humanitarian assistance operations were helpful when placed in the cultural context of Latin America. Premission planning decisions that included time in each port and funding determined the services that were offered to host nations. Surgical, dental, immunizations, preventive medicine, and biomedical repair services had lasting impacts. COMFORT and similar hospital ships are a superior platform to combatant vessels in providing comprehensive surgical care. Medical planning is heavily dependent upon statistics. Collection of additional clinical data on subsequent HCA missions could aid future planning decisions regarding manning, equipment, supplies, and objectives. |
In memoriam: Jonathan S. Allan, DVM (1952-2009)
Chapman LE . Arch Virol 2009 155 (1) 3-5 Jonathan S. Allan, DVM, a 57-year-old internationally respected bioscientist and former mayor of Helotes, Texas, died peacefully at home on 28 September 2009. Jon was diagnosed with a stage 4 glioblastoma, a brain cancer, about 14 months earlier. Jon is survived by two brothers, his mother in New Hampshire, his beloved dog Millie, the wild hogs surrounding his Texas hill country cabin, and a wide community of friends who often met Jon through his science but remained connected primarily because of his humanity. | A native of Boston, Jon earned a Bachelor’s degree at Purdue University in W. Lafayette, Indiana, a Master’s degree in Microbiology at Vanderbilt School of Medicine in Nashville, Tennessee, and a degree in Veterinary Medicine from Michigan State University in East Lansing, Michigan. He returned to Boston in the mid-1980s to complete post-doctoral work in Virology at Harvard University School of Public Health. |
Xenotransplantation, xenogeneic infections, biotechnology, and public health
Chapman LE . Mt Sinai J Med 2009 76 (5) 435-41 Xenotransplantation is the attempt to use living biological material from nonhuman animal species in humans for therapeutic purposes. Clinical trials and preclinical studies have suggested that living cells and tissue from other species have the potential to be used in humans to ameliorate disease. However, the potential for successful xenotransplantation to cure human disease is coupled with the risk that therapeutic use of living nonhuman cells in humans may also serve to introduce xenogeneic infections of unpredictable significance. Animal husbandry practices and xenotransplantation product preparation may eliminate most exogenous infectious agents prior to transplantation. However, endogenous retroviruses are present in the genomes of all mammalian cells, have an inadequately defined ability to infect human cells, and have generated public health concern. The history of xenotransplantation, the implications for public health, the global consensus on public safeguards necessary to accompany clinical trials, and the future direction of xenotransplantation are discussed in the context of public health. Mt Sinai J Med 76:435-441, 2009. (c) 2009 Mount Sinai School of Medicine. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure